Daniel H. Albert

Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy

Joel D. Leverson, Darren C. Phillips, Michael J. Mitten et al. · Science Translational Medicine · 2015 · 541 citations · Full text

Medicine, Oncology, Pharmacology +14

5-lipoxygenase inhibitory activity of zileuton.

G W Carter, Patrick Young, Daniel H. Albert et al. · Journal of Pharmacology and Experimental Therapeutics · 1990 · 420 citations

Medicine, Pharmacokinetics, Pharmacology +13

Selective inhibition of the BD2 bromodomain of BET proteins in prostate cancer

Emily J. Faivre, Keith F. McDaniel, Daniel H. Albert et al. · Nature · 2020 · 404 citations

Life Sciences, Molecular Biology, Oncology +10

Biosynthesis of 1-alkyl-2-acetyl-sn-glycero-3-phosphocholine (platelet-activating factor) from 1-alkyl-2-acyl-sn-glycero-3-phosphocholine by rat alveolar macrophages. Phospholipase A2 and acetyltransferase activities during phagocytosis and ionophore stimulation.

Daniel H. Albert, Fred Snyder · Journal of Biological Chemistry · 1983 · 264 citations · Full text

Life Sciences, Biochemistry, Cell Biology +17

Role of Class I and Class II histone deacetylases in carcinoma cells using siRNA

Keith B. Glaser, Junling Li, Michael J. Staver et al. · Biochemical and Biophysical Research Communications · 2003 · 219 citations

Medicine, Cancer Biology, Oncology +14